Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma - Related Studies

Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

This study is currently recruiting participants.

Study NCT00458913. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Malignant Mesothelioma

2	Additional conditions recognized in this trial
		Mesothelioma

3	More general conditions related to this trial
		Adenoma
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Glandular and Epithelial
		Neoplasms, Mesothelial

4	Interventions listed in this trial
		bortezomib
		cisplatin

5	More general drug interventions related to this trial
		Antineoplastic Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Protease Inhibitors
		Radiation-Sensitizing Agents
		Therapeutic Uses

6	Sponsors listed in this trial
		European Organization for Research and Treatment of Cancer